 | | Vol. 15.39 – 5 October, 2023 |
| |
|
|
| Researchers found that the over-expression of Eyes Absent homolog 4 (EYA4) in breast tissue led to an aggressive and invasive breast cancer phenotype, while the inhibition of EYA4 reduced tumorigenic properties of breast cancer cells in vitro and in vivo.
[Molecular Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors explored whether the direct reduction of therapy sensitivity induced by stroma-produced paracrine factors contributed to the link between stroma and poor responses to chemotherapies.
[Cancer Research] |
|
|
|
| Investigators modeled the spatiotemporal changes promoting chemotherapy resistance in breast cancer. They revealed an important priming phase that rendered cancer cells previously exposed to sublethal drug concentrations refractory to dose escalation.
[Cell Reports] |
|
|
|
| UBE3B depletion inhibited breast cancer cell proliferation, colony formation, migration, and invasion in vitro and suppressed breast tumor growth and lung metastasis in vivo.
[Oncogene] |
|
|
|
| Scientists indicated that the Integrin β4/TNFAIP2/IQGAP1/RAC1 axis provided potential therapeutic targets to overcome DNA damage-related drug resistance in TNBC.
[eLife] |
|
|
|
| Researchers showed that increasing miR-214 expression and decreasing expression of its target gene nuclear factor kappa B subunit 1 in mammosphere-derived epithelial cells abolished 7,12-Dimethylbenz(a)anthracene-induced apoptosis.
[Communications Biology] |
|
|
|
| Scientists established a new cellular model of reversible cellular senescence using lapatinib (LAP) and human epidermal growth factor receptor 2 positive (HER2+) breast cancer cells and found that reversible senescence contributed to LAP resistance in HER2+ breast cancer.
[Cancer Medicine] |
|
|
|
| The authors investigated the effects of vimentin and F‑actin deficiency on the survival and motility of breast cancer cells.
[Oncology Reports] |
|
|
|
| Researchers elucidated the role of LINC00702, a long non-coding RNA, in breast cancer (BC) with bioinformatic and transcriptomic methods. Additionally, they evaluated the impact of LINC00702 knockdown on BC progression.
[Heliyon] |
|
|
|
|
| Scientists summarize that flavonoids represent an essential class of phytochemicals that act as significant regulators of nuclear factor kappa B signaling and negatively affect the fundamental cellular processes.
[Cancer and Metastasis Reviews] |
|
|
|
|
| A breast cancer researcher at the Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center received a five-year, $2.2 million grant from the National Cancer Institute to examine how certain immune cells support metastatic breast cancer development—and how to stop it.
[Indiana University] |
|
|
|
|
| November 15 – 17, 2023
Seoul, Korea |
|
|
|
|
|
| | NYU Medical Center – New York, New York, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | Cold Spring Harbor Laboratory – Cold Spring Harbor, New York, United States |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
